-+ 0.00%
-+ 0.00%
-+ 0.00%
VolitionRx Highlights Diagnostic Licensing Talks, Cancer Detection Progress And Debt Reduction Of Over $5M
Share
Listen to the news

Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic companies worldwide, an expanded Fujifilm agreement to include cats, and over $5 million of debt reduction

HENDERSON, Nev., Nov. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today highlights the progress it has made across its Nu.Q® platform in 2026. Volition now has wide-ranging clinical evidence, partner programs and licensing discussions in place across its key product pillars, each targeting multi-billion-dollar markets.

  • Volition is in discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies to licence its proprietary platform protected by over 70 patents.
  • Volition's model is to co-develop with third parties and license its technology for upfront and milestone payments, royalties and other recurring revenue, while keeping its own costs low.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending